Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAKR.L Regulatory News (AKR)

  • There is currently no data for AKR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BreathScan Alcohol Detection - Product Extension

9 Jun 2010 07:00

RNS Number : 2718N
Akers Biosciences, Inc.
09 June 2010
 

Embargoed: 0700hrs, 9 June 2010

 

 

Akers Biosciences, Inc.

("ABI" or the "Company")

 

ABI Releases BreathScan PRO to Merge Disposable Convenience and Quantitative Precision

 

Akers Biosciences, Inc (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces the initiation of production of a BreathScan alcohol detection product line extension designed for forensic use by trained professionals in law enforcement and other applicable markets, merging the convenience of the Company's proprietary breath alcohol detection technology with the quantitative precision of an electronic analyzer. The System will be branded under the trade name BreathScan PRO and will allow users to determine a subject's breath alcohol level within the range of 0.00% to 0.15%. A test result that is calculated above that range will display on the analyzer's digital read-out as ">0.15%".

The BreathScan PRO system will utilize a specially formulated disposable alcohol detector to collect a breath sample from each test subject. The used detector is then inserted into the BreathScan PRO digital analyzer to obtain a quantitative breath alcohol level for each individual.

Initially, the system will be marketed worldwide for forensic use by trained professionals, including those in civil and military law enforcement, human resources, educational supervision and other safety-related occupations. Some of the scenarios for product use within the "forensic" marketplace will include the following:

·; breath alcohol screenings that seek to quickly and safely establish probable cause for further sobriety or evidential testing by police officers;

·; the assessment of compliance with alcohol safety initiatives related to correctional facilities, work-release programs, employee testing, and school-related events.

User studies are underway to support the Company's application for 510(k) clearance by the US Food and Drug Administration. ABI will seek an Over-the-Counter designation which would further expand the user base of the product in the United States.

ABI will be opening pre-sale of the BreathScan PRO system to its existing distribution network immediately and anticipate that the delivery of the product will commence in September 2010. Product launch to new distributors worldwide will begin early Q4 2010.

Some of the functional highlights of the BreathScan PRO system include the following:

 

·; The one-to-one ratio between breath alcohol detector and breath sample translates into a number of advantages. For one, using the portable BreathScan PRO detectors, several professionals can obtain breath alcohol samples from many test subjects at multiple points of entry/exit. The detectors can then be interpreted by the digital analyzer from within 2 minutes to as long as one hour after the breath sample is obtained. In addition, there is no threat of cross contamination that may exist with other electronic screening devices; those units require numerous persons to provide a breath sample directly into one electronic analyzer.

·; The BreathScan PRO digital analyzer is factory calibrated and never requires recalibration unlike existing screening devices. As a result, organizations that adopt the BreathScan PRO system do not have to factor in system down-time or added expenses related to recalibration activities.

 

·; Unlike most screening devices, BreathScan PRO can be stored and operated at a wide range of temperature conditions(-15C to 50C).

 

Thomas A. Nicolette, President and Chief Executive of ABI, commented,

 

"BreathScan PRO uniquely combines the advantages of one-time use technology with digital sample analysis. The integration of an enduring, electronic reader with custom-calibrated, BreathScan PRO disposable detectors continues our business model focused on recurring revenues. From a competitive standpoint, we are confident that the many advantages of this line extension will be attractive to the global marketplace."

Enquiries:

Thomas A. Nicolette

President and CEO

Tel. +1 856 848 8698

Ben Simons

M: Communications

Tel. +44 (0)20 7920 2340

 

Simon Leathers

Daniel Stewart

Tel. +44 (0)20 7776 6550

 

 

About Akers Biosciences, Inc.

 

Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. ABI has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and it products can be found at www.akersbiosciences.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCZVLFBBQFEBBQ
Date   Source Headline
31st Dec 20157:00 amRNSIssue of Equity & Directors' Shareholdings
1st Dec 20157:00 amRNSAkers Biosciences Updates on JV in China
23rd Nov 20157:00 amRNSAppointment of CEO
13th Nov 20157:00 amRNS3rd Quarter Results
12th Nov 201512:00 pmRNSAppointment of Non-Executive Director
11th Nov 20157:00 amRNSNotice of Q3 Results
4th Nov 20157:00 amRNSHIT Test Approved by Chinese FDA
6th Oct 20157:00 amRNSCommercialization of New Breath Tests
30th Sep 20157:00 amRNSDistribution Agreements
14th Sep 20157:00 amRNSLaunch of Breath Ketone test
18th Aug 20157:00 amRNSHalf Yearly Report
14th Aug 20157:00 amRNSNotice of Half Yearly Results
13th Aug 20157:00 amRNSNotice of Half Yearly Results
3rd Aug 20155:29 pmRNSResult of AGM
30th Jun 20152:00 pmRNSAppointment of Non-Executive Director
25th Jun 20155:00 pmRNSAdjournment of Annual General Meeting
16th Jun 20152:30 pmRNSUpdate on Rapid Breath Tests for Wellness Industry
5th Jun 20153:45 pmRNSNotice of AGM and Proposed Board Changes
14th May 20157:00 amRNS1st Quarter Results
12th May 20157:20 amRNSAkers Introduces New Rapid Breath Tests
11th May 20155:50 pmRNSNotice of Q1 Results
11th May 20157:00 amRNSClaim Against ChubeWorkx Guernsey Limited
6th May 20157:01 amRNSResale Agreement
13th Apr 20157:00 amRNSDistribution Agreements
2nd Apr 20157:00 amRNSDistribution Agreement
23rd Mar 201510:52 amRNSFinal Results
19th Mar 20157:00 amRNSNotice of Results
9th Feb 201512:00 pmRNSAkers' Management System Certified to ISO 13485
26th Jan 20157:00 amRNSEuropean Patent Granted
20th Jan 20157:00 amRNSExpansion of US Sales Effort with Key Appointments
9th Jan 20153:03 pmRNSIssue of Equity
9th Jan 20157:00 amRNSIncentive Stock and Award Plan
18th Dec 20147:00 amRNSEuropean Distribution Agreements
10th Dec 20147:00 amRNSOrder to Supply PIFA Products to China
13th Nov 201412:00 pmRNSThird Quarter Results
10th Nov 201412:00 pmRNSNotice of Third Quarter Results
4th Nov 20144:49 pmRNSResult of AGM
23rd Oct 20141:20 pmRNSJV to Market Rapid Diagnostic Tests in China
17th Oct 20143:10 pmRNSNotice of AGM
16th Sep 20145:53 pmRNSAKERS BIOSCIENCES FEATURES ON GLOBAL MEDIA
9th Sep 201412:30 pmRNSSALES CONTRACT FOR RAPID CHOLESTEROL TEST
8th Sep 20147:00 amRNSChange of Adviser
15th Aug 20147:00 amRNSAppointment of Co-chairman
12th Aug 201411:00 amRNSHalf Yearly Report
5th Aug 20147:00 amRNSSenior Managerial Appointment
28th Jul 20147:00 amRNSFeasibility Study For Heart Attack Test
17th Jul 20147:00 amRNSUS Patent - Breath Ketone Detection Device
30th Jun 20147:00 amRNSPosting of Annual Report and Accounts
25th Jun 20147:00 amRNSUS Distribution Agreement
13th Jun 201411:11 amRNSGrant of Options and Directors Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.